Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging PharmaGlobeNewsWire · Sep 17, 2026
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessGlobeNewsWire · Aug 13, 2026
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic ProfileGlobeNewsWire · Aug 11, 2026
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent PsychopharmacologyGlobeNewsWire · Jul 30, 2026Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.63 | -$0.45 | Beat |
| May 14, 2026 | -$0.53 | -$0.95 | Miss |
| Mar 18, 2026 | -$0.56 | -$0.84 | Miss |
| Nov 13, 2025 | -$0.80 | -$1.35 | Miss |
| Aug 19, 2025 | -$0.82 | -$1.09 | Miss |
| May 8, 2025 | -$1.00 | -$1.04 | Miss |